Real-world costs of ischemic stroke by discharge status

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation 2016;133:e38-360
   PubMed Web of Science ®Google Scholar
• Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947
   PubMed Web of Science ®Google Scholar
• Collen D, Lijnen HR. The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol 2009;29:1151-5
   PubMed Web of Science ®Google Scholar
• Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012;379:2364-72
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Guzauskas GF, Chen E, et al. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke current evidence. Stroke 2014;45:3032-9
   PubMed Web of Science ®Google Scholar
• Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 1998;50:883-90
   PubMed Web of Science ®Google Scholar
• Sinclair SE, Frighetto L, Loewen PS, et al. Cost–utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 2001;19:927-36
   PubMed Web of Science ®Google Scholar
• Sandercock P, Berge E, Dennis M, et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004;35:1490-7
   PubMed Web of Science ®Google Scholar
• Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 2002;5:82-97
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Guzauskas G, Villa KF, et al. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med 2013;61:46-55
   PubMed Web of Science ®Google Scholar
• Moodie ML, Carter R, Mihalopoulos C, et al. Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke. Stroke 2004;35:1041-6
   PubMed Web of Science ®Google Scholar
• Reed SD, Blough DK, Meyer K, Jarvik JG. Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology 2001;57:305-14
   PubMed Web of Science ®Google Scholar
• Caro JJ, Huybrechts KF. Stroke Treatment Economic Model (STEM) predicting long-term costs from functional status. Stroke 1999;30:2574-9
   PubMed Web of Science ®Google Scholar
• Caplan LR. Stroke thrombolysis – growing pains. Mayo Clin Proc 1997;72:1090-2
   PubMed Web of Science ®Google Scholar
• Del Zoppo GJ, Saver JL, Jauch EC, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945-8
   PubMed Web of Science ®Google Scholar
• Goldstein LB. Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: effect of modifier codes. Stroke 1998;29:1602-4
   PubMed Web of Science ®Google Scholar
• Benesch C, Witter DM Jr, Wilder AL, et al. Inaccuracy of the International Classification of Diseases (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease. Neurology 1997;49:660-4
   PubMed Web of Science ®Google Scholar
• Reker DM, Hamilton BB, Duncan PW, et al. Stroke: who’s counting what? J Rehabil Res Dev 2001;38:281-9
   PubMed Web of Science ®Google Scholar
• Consumer Price Index – Medical Care Services. Available at: http://data.bls.gov/cgi-bin/surveymost?cu [Last accessed 19 February 2016]
   Google Scholar
• SAS 9.4. Cary, NC: SAS Institute Inc., 2013
   Google Scholar
• Demaerschalk BM, Hwang HM, Leung G. US cost burden of ischemic stroke: a systematic literature review. Am J Manag Care 2010;16:525-33
   PubMed Web of Science ®Google Scholar
• Kind AJ, Smith MA, Liou JI, et al. The price of bouncing back: one-year mortality and payments for acute stroke patients with 30-day bounce-backs. J Am Geriatr Soc 2008;56:999-1005
   PubMed Web of Science ®Google Scholar
• Lee WC, Christensen MC, Joshi AV, Pashos CL. Long-term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis 2007;23:57-65
   PubMed Web of Science ®Google Scholar
• Leibson CL, Hu T, Brown RD, et al. Utilization of acute care services in the year before and after first stroke: a population-based study. Neurology 1996;46:861-9
   PubMed Web of Science ®Google Scholar
• Lipscomb J, Ancukiewicz M, Parmigiani G, et al. Predicting the cost of illness: a comparison of alternative models applied to stroke. Med Decis Making 1998;18(2 Suppl):S39-S56
   PubMedGoogle Scholar
• Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: a Medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999;30:338-49
   PubMed Web of Science ®Google Scholar
• Sloss EM, Wickstrom SL, McCaffrey DF, et al. Direct medical costs attributable to acute myocardial infarction and ischemic stroke in cohorts with atherosclerotic conditions. Cerebrovasc Dis 2004;18:8-15
   PubMed Web of Science ®Google Scholar
• Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke 1996;27:1459-66
   PubMed Web of Science ®Google Scholar
• Landon BE, Zaslavsky AM, Saunders R, et al. A comparison of relative resource use and quality in Medicare Advantage health plans versus traditional Medicare. Am J Manag Care 2015;21:559-66
   PubMed Web of Science ®Google Scholar
• Landon BE, Zaslavsky AM, Saunders RC, et al. Analysis of Medicare Advantage HMOs compared with traditional Medicare shows lower use of many services during 2003–09. Health Aff (Millwood) 2012;31:2609-17
   PubMed Web of Science ®Google Scholar